Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
- PMID: 36817764
- PMCID: PMC9932042
- DOI: 10.3389/fmed.2023.1066021
Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival rates for patients diagnosed with advanced disease is lower than 50%. The Epidermal Growth Factor Receptor (EGFR) has emerged as an established oncogene in HNSCC. Indeed, although HNSCCs are a heterogeneous group of cancers which differ for histological, molecular and clinical features, EGFR is overexpressed or mutated in a percentage of cases up to about 90%. Moreover, aberrant expression of the other members of the ErbB receptor family, ErbB2, ErbB3 and ErbB4, has also been reported in variable proportions of HNSCCs. Therefore, an increased expression/activity of one or multiple ErbB receptors is found in the vast majority of patients with HNSCC. While aberrant ErbB signaling has long been known to play a critical role in tumor growth, angiogenesis, invasion, metastatization and resistance to therapy, more recent evidence has revealed its impact on other features of cancer cells' biology, such as the ability to evade antitumor immunity. In this paper we will review recent findings on how ErbB receptors expression and activity, including that associated with non-canonical signaling mechanisms, impacts on prognosis and therapy of HNSCC.
Keywords: Cetuximab; EGFR; ErbB receptors; head and neck squamous cell carcinoma; immune checkpoint inhibitors.
Copyright © 2023 Palumbo, Benvenuto, Focaccetti, Albonici, Cifaldi, Rufini, Nardozi, Angiolini, Bei, Masuelli and Bei.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9932042/bin/fmed-10-1066021-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9932042/bin/fmed-10-1066021-g002.gif)
Similar articles
-
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.Clin Cancer Res. 2006 Jul 1;12(13):4103-11. doi: 10.1158/1078-0432.CCR-05-2404. Clin Cancer Res. 2006. PMID: 16818711
-
ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.Oral Dis. 2010 Nov;16(8):774-80. doi: 10.1111/j.1601-0825.2010.01687.x. Oral Dis. 2010. PMID: 20604875
-
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.J Pathol. 2004 Nov;204(3):317-25. doi: 10.1002/path.1642. J Pathol. 2004. PMID: 15476268
-
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.Onco Targets Ther. 2016 Apr 4;9:1927-43. doi: 10.2147/OTT.S93720. eCollection 2016. Onco Targets Ther. 2016. PMID: 27110122 Free PMC article. Review.
-
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).Cancer Treat Rev. 2014 May;40(4):567-77. doi: 10.1016/j.ctrv.2013.10.002. Epub 2013 Oct 12. Cancer Treat Rev. 2014. PMID: 24216225 Review.
Cited by
-
Clinicopathological Parameters and Biomarker Profile in a Cohort of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).Cureus. 2023 Jul 15;15(7):e41941. doi: 10.7759/cureus.41941. eCollection 2023 Jul. Cureus. 2023. PMID: 37588336 Free PMC article.
-
Clinicopathological Parameters Predicting Nodal Metastasis in Head and Neck Squamous Cell Carcinoma.Cureus. 2023 Jun 21;15(6):e40744. doi: 10.7759/cureus.40744. eCollection 2023 Jun. Cureus. 2023. PMID: 37485190 Free PMC article.
-
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. eCollection 2023. Front Immunol. 2023. PMID: 37457699 Free PMC article. Review.
-
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.J Immunother Cancer. 2023 Jun;11(6):e007162. doi: 10.1136/jitc-2023-007162. J Immunother Cancer. 2023. PMID: 37321663 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous